Novo Nordisk
CPSE:NOVO B Community- 2 Narratives written by author
- 3 Comments on narratives written by author
- 493 Fair Values set on narratives written by author
UN
Unike
Community Contributor
Novo Nordisk will dominate with GLP-1 products boosting an 8% revenue spike
Catalysts Are there any products or services that could move sales or earnings meaningfully? Most Immediate Catalyst (1–2 Years): Established GLP-1 Products: Ozempic & Rybelsus: driving robust sales and market penetration.
View narrativeDKK 1.10k
FV
42.9% undervalued intrinsic discount8.00%
Revenue growth p.a.
10users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
9 days ago author updated this narrative
WA
Consensus Narrative from 24 Analysts
R&D And Acquisitions Will Broaden Portfolio Across Multiple Diseases
Key Takeaways Strategic market expansion and supply chain investments are set to boost Novo Nordisk's revenue growth through increased production and broader geographical reach. Diversification through R&D and strategic acquisitions will enhance portfolio breadth, tapping new revenue streams and improving operational efficiencies.
View narrativeDKK 824.65
FV
23.6% undervalued intrinsic discount16.99%
Revenue growth p.a.
5users have liked this narrative
0users have commented on this narrative
128users have followed this narrative
23 days ago author updated this narrative